2030 年までのヨーロッパてんかん市場予測 - 地域別分析 - タイプ別 (進行性ミオクロニーてんかん、反射性てんかん、全般てんかん、その他)、投与経路別 (経口、非経口、その他)、治療タイプ別 (第 1 世代の医薬品、第 2 世代の医薬品、第 3 世代の医薬品)、年齢層別 (成人および小児)、流通チャネル別 (病院薬局、小売薬局、その他)
てんかん治療の開発への投資の増加がヨーロッパのてんかん市場を牽引
ヘルスケア分野は急速な技術開発と革新により変革しており、ヘルスケアサービスとケアの質が向上しています。てんかん市場は、さまざまな成長戦略を実行している小規模および大規模の企業や組織がいくつか存在していることが特徴です。資金が利用可能であるため、企業や組織は生産レベルを向上させ、新しい市場に拡大し、新しい/改良された技術に投資し、研究開発にさらに多くのリソースを割り当てることができます。市場の進歩に貢献しているてんかん市場への注目すべき投資のいくつかを以下に挙げます。
• 2023年3月、スウェーデン政府は、細胞療法や遺伝子療法などの他の先進的治療法の商業化、技能開発、生産能力増強のための国家イノベーションクラスターを設立するため、スウェーデンのイノベーション機関であるVinnovaに総額770万米ドル（8,000万スウェーデンクローナ）を委託することを決定しました。
• 2022年11月、小児てんかんの発症を防ぐための新薬治療の開発プロジェクトに取り組んでいる英国アストン大学の科学者らは、脳内の疾患メカニズムとてんかん予防法の発見のため240万米ドル（200万ポンド）を授与されました。医学研究評議会が資金提供するこの3年間のプロジェクトは、アストン大学健康生命科学部の研究者がブリストル大学およびジャズ・ファーマシューティカルズと共同で実施するものです。
• 2022年7月、Cerebral Therapeuticsは、植え込み型点滴てんかん治療薬をフェーズ3の開発に備えるため、シリーズCラウンドの資金調達で4,000万米ドルを確保しました。この資金調達ラウンドは、RA Capital ManagementやPerceptive Advisorsなどの投資家とともにLynx1 Capital Managementが主導しました。Cerebral Therapeuticsは、経口製剤研究の被験者で目撃された体重増加を引き起こすことなく、指定されたレベルのバルプロ酸を中枢神経系に送達することを意図しています。
• 2021年11月、インディアナ州に拠点を置くスタートアップであるNeuravaは、Elevate Venturesが主導し、Purdue Foundry、UCB Biopharma、First Leaf Capital、iO Life Ventures、エンジェル投資家が参加したシード資金として65万米ドル以上を調達しました。同社は、てんかんによる突然の予期せぬ死の危険が迫っていることをユーザーを監視して警告するウェアラブルデバイスの開発に取り組んでいます。
• 2021年6月、バイオ医薬品企業であるNeurona Therapeutics Inc.は、慢性焦点性てんかんの治療のための抑制性神経細胞療法であるNRTX-1001（第1/2a相臨床試験）を含む、さまざまな適応症に対する同社の完全所有の既製細胞療法のパイプラインを前進させるため、4,150万米ドルの資金調達を成功裏に完了しました。
したがって、高度な治療法の開発への投資の増加がてんかん市場の成長を促進します。
ヨーロッパてんかん市場の概要
ヨーロッパのてんかん市場は、ドイツ、イギリス、フランス、イタリア、スペイン、その他のヨーロッパに分かれています。この地域はてんかん市場で大きな市場シェアを占めています。欧州てんかん市場は、高齢者人口の大幅な増加、規制当局による新薬の承認、同地域での発作に対する効果的な薬や治療法の改善と開発に対する政府による資金の増加などの要因により、予測期間中に大幅な成長が見込まれています。
欧州てんかん市場の収益と2030年までの予測（百万米ドル）
欧州てんかん市場のセグメンテーション
欧州てんかん市場は、タイプ、投与経路、治療タイプ、年齢層、流通チャネル、および国に分類されています。
タイプに基づいて、欧州てんかん市場は、進行性ミオクロニーてんかん、反射てんかん、全般てんかん、その他に分類されています。全般てんかんセグメントは、2022年に最大の市場シェアを占めました。
投与経路に関しては、欧州てんかん市場は経口、非経口、その他に分類されています。 2022年には経口セグメントが最大の市場シェアを占めました。
治療タイプ別に見ると、ヨーロッパのてんかん市場は、第一世代の薬、第二世代の薬、第三世代の薬に分類されています。2022年には第三世代の薬のセグメントが最大の市場シェアを占めました。
年齢層別に見ると、ヨーロッパのてんかん市場は成人と小児に分かれています。2022年には成人セグメントがより大きな市場シェアを占めました。
流通チャネル別に見ると、ヨーロッパのてんかん市場は、病院薬局、小売薬局、その他に分類されています。2022年には病院薬局セグメントが最大の市場シェアを占めました。
国別に見ると、ヨーロッパのてんかん市場は、英国、ドイツ、フランス、イタリア、スペイン、その他のヨーロッパに分かれています。 2022年、ヨーロッパのてんかん市場シェアは英国が独占しました。
ヨーロッパのてんかん市場で事業を展開している大手企業には、アボット ラボラトリーズ、ファイザー、エーザイ、UCB SA、コンビジーン AB、リバノバ、ノバルティス AG、メドトロニック、GSK、H. ルンドベック ASなどがあります。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Europe Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Europe Analysis
6.1 Europe: Epilepsy Market
7. Europe Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Europe Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Europe Epilepsy Market - Country Analysis
12.1 Europe: Epilepsy Market Overview
12.1.1 Europe: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 United Kingdom: Epilepsy Market Overview
12.1.1.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
12.1.1.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Germany: Epilepsy Market Overview
12.1.1.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Germany: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Germany: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 France: Epilepsy Market Overview
12.1.1.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 France: Epilepsy Market Breakdown, by Type
12.1.1.6.2 France: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 France: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 France: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Spain: Epilepsy Market Overview
12.1.1.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Spain: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Spain: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.9 Italy: Epilepsy Market Overview
12.1.1.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.10.1 Italy: Epilepsy Market Breakdown, by Type
12.1.1.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
12.1.1.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
12.1.1.10.4 Italy: Epilepsy Market Breakdown, by Age Group
12.1.1.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.11 Rest of Europe: Epilepsy Market Overview
12.1.1.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
12.1.1.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
12.1.1.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
12.1.1.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
12.1.1.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 CombiGene AB
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 LivaNova Plc
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Medtronic Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 GSK Plc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 H. Lundbeck AS
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
?
List of Tables
Table 1. Europe Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
Table 11. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 32. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 33. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 34. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 35. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 36. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 37. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 38. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 39. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 40. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 41. Recent Organic Growth Strategies in Epilepsy Market
Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. Europe Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in Epilepsy Market
?
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- CombiGene AB
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.